Lilly’s Investigational Dual GIP and GLP-1 Receptor Agonist Shows Significant Reduction in HbA1c and Body Weight in People With Type 2 Diabetes

INDIANAPOLIS, Oct. 4, 2018 /PRNewswire/ — Results from a phase 2b clinical trial of Eli Lilly and Company’s (NYSE: LLY) dual GIP and GLP-1 receptor agonist (GIP/GLP-1 RA, LY3298176) showed strong and clinically meaningful blood sugar reduction and weight loss in people with type 2 diabetes. The six-month data — showing average HbA1c reductions of up to 2.4 percentage points […]

Read more

Genentech Announces New Data for Risdiplam in Spinal Muscular Atrophy (SMA) at the World Muscle Society Congress

South San Francisco, CA — October 3, 2018 — Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today interim clinical data from the dose-finding parts of the pivotal FIREFISH and SUNFISH studies investigating risdiplam (RG7916) in spinal muscular atrophy (SMA). In the FIREFISH study in Type 1 SMA, six out of 14 infants (43 percent) […]

Read more

Opioid-related hospital use up in elderly adults

(HealthDay)—Rates of opioid-related prescriptions and health care utilization are rising among seniors, according to two September statistical briefs released by the Agency for Healthcare Research and Quality (AHRQ). The reports relied on data from the Healthcare Cost and Utilization Project and the Medical Expenditure Panel Survey. Audrey J. Weiss, Ph.D., and colleagues found that among patients 65 years and older, […]

Read more

6 Doctor-Approved Tips For Cold And Flu Season

1. Zinc works 2. There’s nothing wrong with treating (some) symptoms 3. If you’re going use a decongestant, get the one that actually works 4. But avoid decongestants if you have high blood pressure 5. Watch out for acetaminophen 6. Stay home and rest up Source: Read Full Article

Read more

Eisai Announces FDA Approval of Fycompa in Pediatric Patients as Young as 4 Years Old for the Treatment of Partial-Onset Seizures

WOODCLIFF LAKE, N.J., Sept. 28, 2018 /PRNewswire/ — Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) expanded the indication of its antiepileptic drug Fycompa (perampanel) CIII for monotherapy and adjunctive use in pediatric patients 4 years and older for the treatment of partial-onset seizures (POS) with or without secondarily generalized seizures. The approval includes both Fycompa […]

Read more

Brexit will affect the UK’s ability to tackle illicit drugs trade, warn experts

Exclusion from the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) because of Brexit will have serious consequences for public health in the UK, warn experts in a letter to The BMJ this week. The EMCDDA is responsible for conducting surveillance, establishing best practice, facilitating data exchange, providing leadership on new psychoactive substances, and assisting policy makers, they explain. […]

Read more

Genentech’s Investigational Medicine Entrectinib Showed a Durable Response of More Than Two Years in People With a Specific Type of Lung Cancer

South San Francisco, CA — September 24, 2018 — Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced results for its investigational medicine entrectinib, from an integrated analysis of the pivotal Phase II STARTRK-2, Phase I STARTRK-1 and Phase I ALKA trials, which showed that entrectinib shrank tumors (objective response rate; ORR) in 77.4 percent […]

Read more

AbbVie Presents Upadacitinib Longer-Term (32-Week) and Patient-Reported Outcomes Data from Phase 2b Atopic Dermatitis Study at 27th European Academy of Dermatology and Venereology (EADV) Congress

NORTH CHICAGO, Ill., Sept. 13, 2018 /PRNewswire/ — AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced new results from the ongoing Phase 2b study including longer-term (32-week) efficacy and safety data and patient-reported outcomes data evaluating upadacitinib, an investigational, once-daily oral JAK1-selective inhibitor, in adult patients with moderate to severe atopic dermatitis.1,2 Results from a pre-specified, interim analysis […]

Read more

One in four older adults prescribed a benzodiazepine goes on to risky long-term use

They may start as well-intentioned efforts to calm anxiety, improve sleep or ease depression. But prescriptions for sedatives known as benzodiazepines may lead to long-term use among one in four older adults who receive them, according to new research. That’s despite warnings against long-term use of these drugs, especially among older people, because they can increase the risk of car […]

Read more

FDA Approves Imbruvica (ibrutinib) Plus Rituximab for Patients with Waldenström’s Macroglobulinemia

HORSHAM, Pa., August 27, 2018 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) approval of Imbruvica (ibrutinib) in combination with rituximab for the treatment of Waldenström’s macroglobulinemia (WM), a rare blood cancer.[1] The approval expands the label for Imbruvica in WM beyond its current approved use as a monotherapy to […]

Read more
1 … 18 19 20 21 22 … 24